RA total | RA MTX | RA biologic | Control subjects | |
---|---|---|---|---|
No. of subjects | 41 | 12 | 29 | 60 |
Age, years | 58.24 ± 9.72 | 58.67 ± 9.88 | 58.07 ± 9.88 | 58.42 ± 4.41 |
Disease duration. years | 12.15 ± 8.03 | 11.00 ± 8.63 | 12.62 ± 7.87 | – |
RF positivity, % | 70% | 82% | 66% | – |
Anti-CCP positivity, % | 65% | 75% | 64% | – |
MTX duration, years | 6.15 ± 5.82 | 5.83 ± 4.57 | 6.28 ± 3.54 | – |
MTX dose, mg/week | 14.63 ± 6.11 | 14.17 ± 5.15 | 14.83 ± 6.54 | – |
Biologic duration, years | 5.31 ± 2.04 | – | 5.31 ± 2.04 | – |
DAS28 | 2.44 ± 0.87 | 2.88 ± 0.75 | 2.26 ± 0.86 | – |
ESR, mm/h | 17.07 ± 15.09 | 17.00 ± 9.16 | 17.10 ± 17.10 | 5.30 ± 2.40 |
hsCRP, mg/L | 3.93 ± 4.53 | 5.31 ± 3.90 | 3.36 ± 4.70 | 0.30 ± 0.30 |
BMI, kg/m2 | 28.38 ± 5.51 | 28.08 ± 6.77 | 28.51 ± 5.02 | 30.20 ± 8.70 |
TC, mmol/L | 5.34 ± 1.08 | 5.63 ± 1.00 | 5.23 ± 1.10 | 5.27 ± 1.15 |
HDL-C, mmol/L | 1.47 ± 0.43 | 1.38 ± 0.53 | 1.49 ± 0.40 | 1.70 ± 0.42 |
TC/HDL-C ratio | 3.94 ± 1.36 | 4.70 ± 3.73 | 3.73 ± 1.20 | 3.62 ± 0.95 |
LDL-C, mmol/L | 3.17 ± 0.82 | 3.36 ± 0.90 | 3.12 ± 0.81 | 3.40 ± 0.94 |
TG, mmol/L | 1.46 ± 0.68 | 1.53 ± 0.76 | 1.43 ± 0.66 | 1.49 ± 0.61 |
Lp(a), ng/L | 260.14 ± 317.20 | 345.29 ± 426.55 | 239.59 ± 290.74 | – |
ApoA/ApoB ratio | 1.81 ± 0.51 | 1.71 ± 0.49 | 1.83 ± 0.53 | – |